LEXICON PHARMACEUTICALS, INC. (LXRX)
LEXICON PHARMACEUTICALS, INC. (LXRX) from its SEC filings: 2025 revenue $49.8 million (+60% vs the year before), net margin -101%, free cash flow -$67.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $49.8 million |
| Revenue growth | +60% |
| Net income | -$50.3 million |
| Net margin | -101.1% |
| Free cash flow | -$67.9 million |
| Diluted EPS | $-0.14 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -98% |
| Cash | $40.9 million |
| Long-term debt | $51.4 million |
| Share count, 1 year | +22% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.